Subscribe to Newsletter

February 2021 Issue of The Medicine Maker

In this issue, Upfront covers resilient supply chains, vaccine wars, and a gene therapy showing remarkable results in paralyzed animals. The focus of our cover feature is COVID-19; we gather experts from different sectors of the pharma industry to discuss how the pandemic has affected leadership and communication. Also in this issue: Ewoud van Tricht discusses analytical methods for vaccines, Alice Dunbabin talks about the benefits of biocatalysts; and Angela Myers and Michael Lehmicke explain how to standardize advanced therapy manufacture. We also have an interview with Sandy Macrae, CEO of Sangamo.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

Business & Regulation Standards & Regulation

Crisis-Ready: Building a Resilient Supply

| Maryam Mahdi

Is the European Union better prepared for future healthcare crises?

Discovery & Development Dosage Forms

Crossing the Border

| Stephanie Vine

How can we get macromolecules across the intestinal epithelial barrier?

Business & Regulation Standards & Regulation

Vaccine Wars: EU Member States Given Power to Block Certain Vaccine Exports

| James Strachan

New EU “transparency” measures give member states the power to block vaccine exports if manufacturers can’t meet contractual obligations.

Discovery & Development Advanced Medicine

Paralyzed Mice Walk Again

| James Strachan

Mice with severed spinal cords walk again after gene therapy.

Business & Regulation Contract Development Services

Keeping Your Nose in Front

| Charles Evans

With the right partner to help you harness the many benefits, nasal delivery is not to be sniffed at.

Business & Regulation Business Practice

Big Pharma: Heal Thyself

| Barry Silverstein

Pharma hasn’t always covered itself in glory – but as the world scrambles for viable COVID-19 interventions, it has a rare opportunity to rebrand.

Discovery & Development Formulation

The Inhalation Advantage

| Sponsored by Vectura

Vectura has more than 20 years’ experience in helping customers bring inhaled medicines to the market.

Business & Regulation Business Practice

COVID-19: A Year of Unprecedented Change

| Maryam Mahdi

What role have small molecules played in the fight against COVID-19?

Business & Regulation Advanced Medicine

Leadership in Times of Crisis

| Stephanie Vine

Experts from our previous Power Lists discuss the challenges of leadership during these trying times.

Manufacture Bioprocessing - Upstream & Downstream

Capturing Value in Changing Times

| Sponsored by Thermo Fisher Scientific

The increasing complexity of biologics raises significant manufacturing challenges – not least regarding cost control and downstream purification.

Discovery & Development COVID-19

Better Methods for Better Vaccines

| Ewoud van Tricht

Ewoud van Tricht explores three novel methods that could streamline the development of adenovirus vaccines for COVID-19 at Janssen.

Manufacture Small Molecules

Are You a Bio-Catalytic Converter?

| Alice Dunbabin

Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.

Manufacture Standards & Regulation

How to Standardize Advanced Therapy Manufacture

| James Strachan

Cell and gene therapy manufacturing technologies and methods are advancing rapidly, but can regulators keep up?

Discovery & Development Drug Delivery

Painting the Future of Drug Delivery

| James Strachan

US Army combat veteran Luis Alvarez has developed a new drug delivery technology that can convert recombinant proteins into material-binding variants.

Manufacture Advanced Medicine

Of Plumbing and Poetry

| James Strachan

We Sit Down With Sandy Macrae, Chief Executive Officer, Sangamo Therapeutics, USA.

Other issues of 2021